- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Researchers Develop Experimental Drug That Reverses Severe Fatty Liver Disease - Video
Overview
Could repairing the gut be the key to treating severe fatty liver disease? Researchers have developed an experimental drug that reversed advanced fatty liver disease in animal studies by restoring the gut's protective barrier rather than targeting the liver directly.
The study, published in The Journal of Clinical Investigation, investigated DT-109, a glycine-based tripeptide developed at Michigan Medicine. Scientists believe it could offer a new treatment approach for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease that can progress to cirrhosis, liver cancer, and liver failure.
The researchers found that an overgrowth of the gut bacterium Clostridium perfringens increased ammonia production in the intestines. Excess ammonia damaged the gut lining, allowing harmful bacterial products to leak into the bloodstream and reach the liver, where they triggered inflammation and immune activation.
In experiments involving mice and non-human primates, DT-109 reduced C. perfringens levels, lowered intestinal ammonia production, and repaired the gut barrier. By preventing harmful microbial products from entering the bloodstream, the drug reduced liver inflammation and significantly improved MASH.
The benefits were particularly encouraging in non-human primates, whose gut microbiome and liver biology closely resemble those of humans, suggesting the findings may have greater relevance for future clinical research.
Researchers also believe DT-109 could have broader health benefits. Previous studies suggest it may reduce the development of atherosclerosis and vascular calcification, while the restoration of gut barrier function could make it a potential therapy for conditions such as inflammatory bowel disease (IBD).
However, the findings are currently limited to animal studies, and the drug has not yet been tested in people. The research team plans to carry out additional preclinical studies before advancing DT-109 into human clinical trials to evaluate its safety and effectiveness for treating MASH and other diseases linked to gut barrier dysfunction.
REFERENCE: Pengxiang Qu, Shusi Ding, et al.; Metabolic dysfunction–associated steatohepatitis exacerbated by Clostridium perfringens–derived ammonia is attenuated by tripeptide DT-109. Journal of Clinical Investigation, 2026; 136 (13) DOI: 10.1172/JCI200522


